Human Papillomavirus (HPV) and Cytomegalovirus (CMV) Therapeutics Market - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

Human Papillomavirus (HPV) and Cytomegalovirus (CMV) Therapeutics Market - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

Cytomegalovirus (CMV) infections spread through body fluids such as saliva, semen, breast milk, and urine. Signs and symptoms of the infections include, fatigue, fever, diarrhea, pneumonia, and hepatitis, shortness of breath, gastrointestinal ulceration, and bleeding.
Although no treatment for the infection caused by human papillomavirus (HPV) is available, symptoms can be treated. Most sexually active men and women suffer from HPV infections. The infections spread through oral, vaginal or anal sex. HPV can also be transmitted during birth to infant and can lead to genital or respiratory infections.
Market Dynamics
Increasing collaboration activities of major players is expected to propel growth of the human papillomavirus (HPV) and cytomegalovirus (CMV) therapeutics market. For instance, in November 2018, GeoVax Labs Inc. announced collaboration with Virometix. The collaboration focuses on development of therapeutic vaccines for HPV infections. This collaboration will include preclinical animal testing of GeoVax’s MVA-Vectored HPV vaccines candidates in combination with Virometix synthetic HPV vaccines candidates.
Moreover, increasing regulatory approvals for novel therapies is expected to boost the human papillomavirus (HPV) and cytomegalovirus (CMV) therapeutics market growth. For instance, in November 2021, Merck received the U.S. Food and Drug Administration approval for its Prevymis (letermovir) tablets and intravenous (IV) injection for prophylaxis of CMV infections and CMV seropositive recipients.
Key features of the study:
This report provides in-depth analysis of the human papillomavirus (HPV) and cytomegalovirus (CMV) therapeutics market size (US$ Mn), and cumulative annual growth rate (CAGR (%)) for the forecast period (2022-2028), considering 2021, as the base year
It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global human papillomavirus (HPV) and cytomegalovirus (CMV) therapeutics market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies
Key players covered as a part of this study include, , Allergan, Bausch Health, GlaxoSmithKline, Lee’s Pharmaceutical Holdings, Merck Sharp & Dohme, Fougera Pharmaceuticals, Clinigen Group plc., Perrigo Company plc., Roche Holding AG, Biotest AG, and Fresenius Kabi
Insights from this report would allow marketers and management authorities of companies to make informed decision with respect to their future product launch, governmental initiatives, technological up-gradation, market expansion, and marketing tactics
The global human papillomavirus (HPV) and cytomegalovirus (CMV) therapeutics market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors and suppliers for anesthesia device market, research and consulting firms, new entrants, and financial analysts

Detailed Segmentation:
Global human papillomavirus (HPV) and cytomegalovirus (CMV) therapeutics market, By Drug Type:
HPV Therapeutics
Immunomodulatory Agents
Interleukins
Cytokines
Chemokine
Others
Keratolytic Agents
TCA (Trichloroacetic Acid)
Bichloracetic Acid
Anti-neoplastic Agents
Sinecatechins
CMV Therapeutics
Ganciclovir/Valganciclovir
Foscarnet
Cidifovir
Human papillomavirus (HPV) and cytomegalovirus (CMV) therapeutics market, By Application:
HPV Therapeutics Application
Genital warts
Cervical cancer
Epidermodysplasia Verrucifdormis
Others
CMV Therapeutics Application
CMV Retinitis
Pneumonia
Gastrointestinal ulcers
Encephalitis
Others
Human papillomavirus (HPV) and cytomegalovirus (CMV) therapeutics market, By Distribution Channel:
Hospitals Pharmacies
Retail Pharmacies
Online Pharmacies
Human papillomavirus (HPV) and cytomegalovirus (CMV) therapeutics market, By Region:
North America
By Country:
U.S.
Canada
By Drug Type:
HPV Therapeutics
Immunomodulatory Agents
Interleukins
Cytokines
Chemokine
Others
Keratolytic Agents
TCA (Trichloroacetic Acid)
Bichloracetic Acid
Anti-neoplastic Agents
Sinecatechins
CMV Therapeutics
Ganciclovir/Valganciclovir
Foscarnet
Cidifovir
By Application
HPV Therapeutics Application
Genital warts
Cervical cancer
Epidermodysplasia Verrucifdormis
Others
CMV Therapeutics Application
CMV Retinitis
Pneumonia
Gastrointestinal ulcers
Encephalitis
Others
By Distribution Channel:
Hospitals Pharmacies
Retail Pharmacies
Online Pharmacies
Europe
By Country:
U.K.
Germany
Italy
Spain
France
Russia
Rest of Europe
By Drug Type:
HPV Therapeutics
Immunomodulatory Agents
Interleukins
Cytokines
Chemokine
Others
Keratolytic Agents
TCA (Trichloroacetic Acid)
Bichloracetic Acid
Anti-neoplastic Agents
Sinecatechins
CMV Therapeutics
Ganciclovir/Valganciclovir
Foscarnet
Cidifovir
By Application
HPV Therapeutics Application
Genital warts
Cervical cancer
Epidermodysplasia Verrucifdormis
Others
CMV Therapeutics Application
CMV Retinitis
Pneumonia
Gastrointestinal ulcers
Encephalitis
Others
By Distribution Channel:
Hospitals Pharmacies
Retail Pharmacies
Online Pharmacies
Asia Pacific
By Country:
Australia
India
China
Japan
ASEAN
South Korea
Rest of Asia Pacific
By Drug Type:
HPV Therapeutics
Immunomodulatory Agents
Interleukins
Cytokines
Chemokine
Others
Keratolytic Agents
TCA (Trichloroacetic Acid)
Bichloracetic Acid
Anti-neoplastic Agents
Sinecatechins
CMV Therapeutics
Ganciclovir/Valganciclovir
Foscarnet
Cidifovir
By Application
HPV Therapeutics Application
Genital warts
Cervical cancer
Epidermodysplasia Verrucifdormis
Others
CMV Therapeutics Application
CMV Retinitis
Pneumonia
Gastrointestinal ulcers
Encephalitis
Others
By Distribution Channel:
Hospitals Pharmacies
Retail Pharmacies
Online Pharmacies
Latin America
By Country:
Brazil
Mexico
Argentina
Rest of Latin America
By Drug Type:
HPV Therapeutics
Immunomodulatory Agents
Interleukins
Cytokines
Chemokine
Others
Keratolytic Agents
TCA (Trichloroacetic Acid)
Bichloracetic Acid
Anti-neoplastic Agents
Sinecatechins
CMV Therapeutics
Ganciclovir/Valganciclovir
Foscarnet
Cidifovir
By Application
HPV Therapeutics Application
Genital warts
Cervical cancer
Epidermodysplasia Verrucifdormis
Others
CMV Therapeutics Application
CMV Retinitis
Pneumonia
Gastrointestinal ulcers
Encephalitis
Others
By Distribution Channel:
Hospitals Pharmacies
Retail Pharmacies
Online Pharmacies
Middle East
By Country:
GCC
Israel
Rest of Middle East
By Drug Type:
HPV Therapeutics
Immunomodulatory Agents
Interleukins
Cytokines
Chemokine
Others
Keratolytic Agents
TCA (Trichloroacetic Acid)
Bichloracetic Acid
Anti-neoplastic Agents
Sinecatechins
CMV Therapeutics
Ganciclovir/Valganciclovir
Foscarnet
Cidifovir
By Application
HPV Therapeutics Application
Genital warts
Cervical cancer
Epidermodysplasia Verrucifdormis
Others
CMV Therapeutics Application
CMV Retinitis
Pneumonia
Gastrointestinal ulcers
Encephalitis
Others
By Distribution Channel:
Hospitals Pharmacies
Retail Pharmacies
Online Pharmacies
Africa
By Country/Region:
South Africa
Central Africa
North Africa
By Drug Type:
HPV Therapeutics
Immunomodulatory Agents
Interleukins
Cytokines
Chemokine
Others
Keratolytic Agents
TCA (Trichloroacetic Acid)
Bichloracetic Acid
Anti-neoplastic Agents
Sinecatechins
CMV Therapeutics
Ganciclovir/Valganciclovir
Foscarnet
Cidifovir
By Application
HPV Therapeutics Application
Genital warts
Cervical cancer
Epidermodysplasia Verrucifdormis
Others
CMV Therapeutics Application
CMV Retinitis
Pneumonia
Gastrointestinal ulcers
Encephalitis
Others
By Distribution Channel:
Hospitals Pharmacies
Retail Pharmacies
Online Pharmacies
Company Profiles
GlaxoSmithKline*
Company Overview
Product Portfolio
Financial Performance
Recent Highlights
Strategies
Allergan
Bausch Health
Lee’s Pharmaceutical Holdings
Merck Sharp & Dohme
Fougera Pharmaceuticals
Clinigen Group plc.
Perrigo Company plc.
Roche Holding AG
Biotest AG
Fresenius Kabi
“*” marked represents similar segmentation in other categories in the respective section.